Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Diego, California (PRWEB) April 24, 2015 ... announced key milestones in its allogeneic stem-cell product ... Biopharma to properly reflect the corporate strategic direction. ... our allogeneic (donor) adipose stem cell development program ... completion of our cGMP manufacturing facility and hiring ...
(Date:4/24/2015)... SAN DIEGO , April 24, 2015  Pfenex ... in the development of biosimilar therapeutics including high value ... of its follow-on public offering of 6,000,000 shares of ... of $15.50 per share. Of the shares being offered, ... 3,390,000 shares are being offered by existing stockholders. Pfenex ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... and BioMed Central are announcing the launch ... today, a new online community for ... opportunities and industry news. (Logo: ... http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100916/FL66006LOGO ...
... The PhD thesis by Carlos Echeverra Arrondo, Doctor in ... "On doped semiconductor quantum dots and magnetic nanowires", studied ... The interest aroused by nanoscience and nanotechnology spurred Dr ... their size is reduced to less than one hundred ...
... SIAL ) will be presenting at the UBS ... 12:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High Technology ...
Cached Biology Technology:BioSpace and BioMed Central Create Global Career Community 2Ph.D. study of behavior of semiconductor crystals of size less than 100 nanometers 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... This press release is available in French . ... Cancer (IRIC) of the Universit de Montral have identified a ... the origin of several cancers. In an article published in ... recent discovery of a protein complex that controls the RAS/MAPK ...
... have discovered a disease mechanism that links hereditary amyotrophic lateral ... and points to a possible therapeutic target. The findings ... Nature Neuroscience . ALS is an adult-onset disease ... three to five years of diagnosis. Scott Brady, ...
... accumulating in municipal landfills, and reliance on imported oil ... new ultra-light biodegradable foam plastic material made from two ... The new substance could be used in furniture cushions, ... ACS, Biomacromolecules , a monthly journal. ...
Cached Biology News:Discovery of a mechanism that controls the expression of a protein involved in numerous cancers 2Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3
...
... Nonanoyl-N-methylglucamide White solid. Water-soluble ... readily removed by dialysis. Useful reagent ... by HPLC. Absorbance (10%, H ... O. CMC 19 - 25 mM. ...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
Biology Products: